Literature DB >> 23215685

Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives.

Maria João Matos1, Alexandra Gaspar, Sonja Kachler, Karl-Norbert Klotz, Fernanda Borges, Lourdes Santana, Eugenio Uriarte.   

Abstract

OBJECTIVES: With the aim of finding the structural features governing binding activity and selectivity against adenosine receptors (ARs), several 3-subtituted coumarins with amide (compounds 3-6) and carbamate (7-9) functions were synthesized. To study its possible influence on the binding activity and selectivity, a hydroxyl substituent was also introduced at position 4 of the coumarin moiety.
METHODS: A new series of coumarins (3-9) were synthesized and evaluated by radioligand binding studies towards ARs. KEY
FINDINGS: None of the 4-hydroxy derivatives (4, 8 and 9) showed binding affinity for any of the ARs. None of the compounds interacted with the hA(2B) AR (K(i) > 100,000 nM). Compounds 3, 5, 6 and 7 had different activity profiles with dissimilar binding affinity and selectivity towards human A₁, A(2A) and A₃ ARs.
CONCLUSIONS: The most remarkable derivative is compound 7, which presents the best affinity and selectivity for the A₃ adenosine receptor (K(i) = 5500 nM).
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23215685     DOI: 10.1111/j.2042-7158.2012.01571.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  2 in total

1.  Design, Synthesis, and Antifungal Activity of 4-Amino Coumarin Based Derivatives.

Authors:  Lu Xu; Jinmeng Yu; Lu Jin; Le Pan
Journal:  Molecules       Date:  2022-04-24       Impact factor: 4.927

Review 2.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.